Various factors are propelling the diabetic retinopathy market growth. Such factors, as per the latest Market Research Future report, include the advancement of patient monitoring, growing awareness about diabetic retinopathy treatment, rising disposable income, increased health awareness, changing lifestyle, and rise in diabetes patients worldwide. Additional factors pushing diabetic retinopathy market growth include an increase in the geriatric population and an increasing prevalence of blindness owing to diabetes.
The global Diabetic Retinopathy Market Size is anticipated to grow at a 11.9% CAGR between 2019-2025, reveals the new Market Research Future (MRFR) report. Diabetic retinopathy, simply put, is a diabetes complication that affects the eyes. It is of two types- proliferative (advanced stage) and non-proliferative (milder form).
On the flip side, lack of insurance facilities, extended time of approval for drugs, and shortage of skilled ophthalmologists are factors that may restrict the diabetic retinopathy market growth during the forecast period.
• BCN Peptides
• Kowa Group
• Ampio Pharmaceuticals
• Glycadia Pharmaceuticals
• Alimera Sciences
• Actavis Plc
• Regeneron Pharmaceuticals Inc
• Novartis AG
• The Global Diabetic Retinopathy Market has been segmented based on type, treatment, end-user, and region.
• The diabetic retinopathy market, based on type, has been segmented into non-proliferative and proliferative.
• The diabetic retinopathy market, based on treatment, has been segmented into anti-VEGF drugs, laser photocoagulation, vitreoretinal surgery, and steroid injection.
• The diabetic retinopathy market, based on end-user, has been segmented into hospitals, ambulatory surgical centers, and others.
By region, the diabetic retinopathy market report covers the latest trends and growth opportunities across the Americas, the Asia Pacific, the Middle East and Africa, and Europe. Of these, the Americas is projected to have the lion’s share in the market during the forecast period. Factors pushing the growth of the diabetic retinopathy market in the region include growing focus on preventive care for different chronic diseases, especially obesity and diabetes, presence of notable players in the region, availability of diagnostic & treatment services, and rising number of specialty care centers. The US is the prime contributor in the region.
The diabetic retinopathy market in Europe will have the second-largest share in the market during the forecast period. Factors pushing the growth of the diabetic retinopathy market in the region include on-going research activities, early diagnosis, focus on constant health monitoring, and rising prevalence of diabetes.